Pfizer’s VYNDAQEL gets EC approval for treatment of ATTR-CM
The approval from the European Commission (EC) makes VYNDAQEL the first and only treatment for patients with ATTR-CM in the European Union (EU). Considered to be a rare,
The company will invest around $109m to develop the 135,000ft² gene therapy manufacturing facility. North Carolina Governor Roy Cooper said: “With our powerhouse research centres and highly-skilled workforce,